

# David Pennisi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1555565/publications.pdf>

Version: 2024-02-01

40  
papers

3,049  
citations

257450

24  
h-index

315739

38  
g-index

103  
all docs

103  
docs citations

103  
times ranked

4642  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence, prevalence, and predictors of inflammatory arthritis in patients with hidradenitis suppurativa: a systematic review and meta-analysis. <i>International Journal of Dermatology</i> , 2022, 61, 1069-1079.	1.0	3
2	Acquired low immunoglobulin levels and risk of clinically relevant infection in adult patients with systemic lupus erythematosus: a cohort study. <i>Rheumatology</i> , 2021, 60, 1456-1464.	1.9	7
3	Immunoglobulin levels in systemic lupus erythematosus: A narrative review. <i>Lupus</i> , 2021, 30, 867-875.	1.6	8
4	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2 "Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1254-1268.	1.2	88
5	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	1.2	43
6	Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis vulgaris (PsV). <i>Scientific Reports</i> , 2020, 10, 4925.	3.3	20
7	Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients With Psoriatic Disease. <i>Arthritis and Rheumatology</i> , 2019, 71, 1651-1659.	5.6	22
8	Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 834-839.	3.4	8
9	Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. <i>RMD Open</i> , 2019, 5, e000585.	3.8	41
10	Comparison Between INSPIRE and Domjan method for measuring lumbar lateral flexion in patients of psoriatic arthritis (PsA) and correlation with radiographic damage. <i>Clinical Rheumatology</i> , 2019, 38, 1063-1066.	2.2	3
11	Psoriatic arthritis. <i>F1000Research</i> , 2019, 8, 1665.	1.6	105
12	The Association Between <sc>HLA</sc> Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 756-762.	5.6	14
13	Imputation-based analysis of MICA alleles in the susceptibility to ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1691-1692.	0.9	14
14	4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. <i>RMD Open</i> , 2018, 4, e000582.	3.8	34
15	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	5.6	72
16	171 Secukinumab provides sustained PASDAS related low disease activity in psoriatic arthritis: two year results from the FUTURE 2 study. <i>Rheumatology</i> , 2018, 57, .	1.9	0
17	Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 415-426.	3.3	1
18	169 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies. <i>Rheumatology</i> , 2018, 57, .	1.9	0

#	ARTICLE	IF	CITATIONS
19	Genome-wide association study in Guillain-Barré syndrome. <i>Journal of Neuroimmunology</i> , 2018, 323, 109-114.	2.3	13
20	Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. <i>Nature Reviews Rheumatology</i> , 2018, 14, 363-371.	8.0	149
21	Functional impairment measurement in psoriatic arthritis: Importance and challenges. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 436-448.	3.4	29
22	From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenile-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 1627-1635.	3.4	42
23	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.9	194
24	Psoriatic arthritis disease activity during pregnancy and the first-year postpartum. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 740-745.	3.4	37
25	Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. <i>New England Journal of Medicine</i> , 2017, 377, 1525-1536.	27.0	405
26	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017, 19, 287.	3.5	1
27	Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. <i>Rheumatology</i> , 2015, 54, 449-457.	1.9	37
28	Fine mapping of eight psoriasis susceptibility loci. <i>European Journal of Human Genetics</i> , 2015, 23, 844-853.	2.8	25
29	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. <i>Nature Genetics</i> , 2011, 43, 761-767.	21.4	778
30	Kidney Development. <i>Current Topics in Developmental Biology</i> , 2010, 90, 193-229.	2.2	98
31	Crim1KST264/KST264 Mice Implicate Crim1 in the Regulation of Vascular Endothelial Growth Factor-A Activity during Glomerular Vascular Development. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1697-1708.	6.1	50
32	A role for Tbx5 in proepicardial cell migration during cardiogenesis. <i>Physiological Genomics</i> , 2004, 18, 129-140.	2.3	88
33	Current and investigational treatment of psoriatic arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 139-150.	4.1	1
34	Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice. <i>Nature Genetics</i> , 2000, 24, 434-437.	21.4	201
35	Atherosclerosis and systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2000, 2, 19-23.	4.7	34
36	Mice Null for <i>Sox18</i> Are Viable and Display a Mild Coat Defect. <i>Molecular and Cellular Biology</i> , 2000, 20, 9331-9336.	2.3	106

#	ARTICLE	IF	CITATIONS
37	An H <sub>2</sub> Db epitope is encoded by a novel mouse Y chromosome gene. <i>Nature Genetics</i> , 1996, 14, 474-478.	21.4	176
38	Musculoskeletal Manifestations of Infection with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1990, 12, 223-235.	5.8	49
39	Severe reflex neurovascular dystrophy in childhood. <i>Arthritis and Rheumatism</i> , 1985, 28, 952-956.	6.7	40
40	Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials. <i>Rheumatology and Therapy</i> , 0, , .	2.3	3